Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Although uveitis is reported as a rare adverse event (AE) associated with dabrafenib/trametinib therapy or nivolumab, the occurrence of severe uveitis is extremely rare. We describe two cases of Vogt-Koyanagi-Harada (VKH)-like uveitis developing after the sequential administration of nivolumab and dabrafenib/trametinib therapy. Interestingly, both cases had HLA-DRB1*04:05, which is strongly associated with VKH disease, and achieved biologically complete remission after the treatment for uveitis. Our cases suggest a possible correlation between VKH-like uveitis as an AE and the clinical outcomes of sequential administration of nivolumab and dabrafenib/trametinib therapy for the treatment of advanced melanoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.14273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coexistence of low-grade pulmonary mucinous epithelioid carcinoma and metastatic adrenal sarcomatoid carcinoma: a rare case report with BRAF p.V600E-driven molecular insights and clinical challenges.
Front Oncol
August 2025
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Introduction: Pulmonary mucinous epithelioid carcinoma (PMEC) is a rare malignancy that typically progresses slowly and has a favorable prognosis. In contrast, adrenal sarcomatoid carcinoma (ASC) is an aggressive and uncommon cancer with poor outcomes. The coexistence of low-grade PMEC and metastatic ASC is exceedingly rare and presents unique clinical challenges, with limited treatment options and poor prognosis.
View Article and Find Full Text PDFCutaneous Melanoma: A Review.
JAMA
August 2025
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania.
Importance: Melanoma, the fifth most common cancer in the US, has increased from 8.8 per 100 000 in 1975 to 28.42 per 100 000 in 2022.
View Article and Find Full Text PDFEnhanced response to dabrafenib plus trametinib in a patient with lung cancer harboring an variant of unknown significance: a case report.
Front Oncol
July 2025
Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Background: Literature evidence reports that (ring finger protein 43) gene mutations could serve as predictive biomarkers of response to certain anti-cancer therapies. To delve deeper into the specific role of mutations in lung cancer and their relevance to therapy response, we provide the first report of marked efficacy of the dabrafenib and trametinib therapeutic combination in a patient with microsatellite-stable (MSS) non-small-cell lung cancer (NSCLC) with and mutations.
Case Description: An 85-year-old patient was diagnosed with NSCLC with the presence of MSS, and mutations.
Molecularly driven therapies in the treatment of primary brain tumors.
Adv Cancer Res
July 2025
Sylvester Comprehensive Cancer Center, Division of Neuro-Oncology, Department of Neurology, University of Miami, Miami, FL, United States. Electronic address:
Molecular profiling has revolutionized the diagnosis, classification, and treatment of various cancers, with advances in next-generation sequencing and DNA methylation profiling offering unprecedented insights into tumor biology. This paradigm shift has enhanced the understanding of driver mutations in cancers translating into improved patient outcomes. In primary brain tumors, particularly gliomas, molecular profiling has redefined classification frameworks, yet meaningful improvements in patient survival remain elusive, particularly for glioblastoma.
View Article and Find Full Text PDFRAS pathway targeted therapy in patients with DICER1-associated sarcomas.
NPJ Precis Oncol
July 2025
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
DICER1-associated sarcomas commonly exhibit cooperating mutations involving RAS signaling pathways, but the efficacy of therapies that target these mutations is unknown. Here we report two children with DICER1 tumor predisposition who presented with DICER1-associated sarcomas with cooperating, targetable mutations in HRAS or BRAF. Both had relapsed/progressed disease despite upfront multimodal therapy and were subsequently treated with molecularly targeted agents.
View Article and Find Full Text PDF